{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:05:47Z","timestamp":1789725947608,"version":"4.0.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.kint.2026.07.004","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:29:35Z","timestamp":1789723775000},"page":"792-795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Somatostatin analogues for ADPKD: ending the confusing story of mGFR and eGFR"],"prefix":"10.1016","volume":"110","author":[{"given":"Ron T.","family":"Gansevoort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3649-6948","authenticated-orcid":false,"given":"Thomas","family":"Bais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.07.004_bib1","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/ndt\/gfz054","article-title":"Somatostatin in renal physiology and autosomal dominant polycystic kidney disease","volume":"35","author":"Messchendorp","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.07.004_bib2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.07.004_bib3","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2026.07.004_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002777","article-title":"Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial","volume":"16","author":"Perico","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.kint.2026.07.004_bib5","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2026.07.004_bib9","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.kint.2026.05.018","article-title":"A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2\/3 autosomal dominant polycystic kidney disease","volume":"104","author":"Joly","year":"2026","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.07.004_bib11","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.07.004_bib12","doi-asserted-by":"crossref","first-page":"e0257606","DOI":"10.1371\/journal.pone.0257606","article-title":"Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: a systematic review and meta-analysis of randomized clinical trials","volume":"16","author":"Suwabe","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2026.07.004_bib13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2019.04.018","article-title":"Lanreotide reduces liver growth in patients with autosomal dominant polycystic liver and kidney disease","volume":"157","author":"van Aerts","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.kint.2026.07.004_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40264-016-0486-x","article-title":"Hepatic cyst infection during use of the somatostatin analog lanreotide in autosomal dominant polycystic kidney disease: an interim analysis of the randomized open-label multicenter DIPAK-1 study","volume":"40","author":"Lantinga","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.kint.2026.07.004_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40268-021-00342-7","article-title":"Incident gallstones during somatostatin analog treatment are associated with acute biliary complications especially after discontinuation","volume":"21","author":"Aapkes","year":"2021","journal-title":"Drugs R D"},{"key":"10.1016\/j.kint.2026.07.004_bib16","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1002\/sim.8282","article-title":"Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease","volume":"38","author":"Vonesh","year":"2019","journal-title":"Stat Med"},{"key":"10.1016\/j.kint.2026.07.004_bib17","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1681\/ASN.2015040341","article-title":"Change in measured GFR versus eGFR and CKD outcomes","volume":"27","author":"Ku","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"2S","key":"10.1016\/j.kint.2026.07.004_bib18","first-page":"S1","article-title":"KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)","volume":"107","year":"2025","journal-title":"Kidney Int"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826006186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826006186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:31:40Z","timestamp":1789723900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826006186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0085253826006186"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.07.004","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Somatostatin analogues for ADPKD: ending the confusing story of mGFR and eGFR","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.05.018","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}